Yonsei Med J.  2012 May;53(3):530-536. 10.3349/ymj.2012.53.3.530.

Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant

• Kim Y
• Yoon S
• Kim SJ
• Kim JS
• Cheong JW
• Min YH

• KMID: 1776987
• DOI: http://doi.org/10.3349/ymj.2012.53.3.530

Abstract

PURPOSE
Despite extensive study, the use of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia (AML) vary considerably. The decision of which of these options to choose is complex and depends on both clinical and molecular variables as well as the availability and histocompatability of donor stem cells. So far there is no clear explanation on whether the expression of myeloperoxidase (MPO) relates to the prognosis of AML.
MATERIALS AND METHODS
We retrospectively analyzed the prognostic significance of the MPO expression in the 140 patients with diagnosed AML treated at a single institution.
RESULTS
In our study, MPO expression was associated with disease-free survival (DFS) and transplant was beneficial to overcome a negative prognostic effect of MPO-negative at diagnosis based upon the result that the DFS in patients received transplants are not significant between the MPO-positive group and MPO-negative group although DFS in all patients was different according to MPO expression.
CONCLUSION
MPO expression at diagnosis helps to choose therapy for each AML patient and can differentiate AML patients who need transplantation.

Keyword

Myeloperoxidase; acute myeloid leukemia; prognostic factor; transplant

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Cytarabine/therapeutic use
Disease-Free Survival
Female
Flow Cytometry
Hematopoietic Stem Cell Transplantation
Humans
Idarubicin/therapeutic use
Immunophenotyping
Leukemia, Myeloid, Acute/drug therapy/*enzymology/mortality/*therapy
Male
Middle Aged
Peroxidase/*metabolism
Retrospective Studies
Young Adult

Figure

• 

  Fig. 1 (A) OS by MPO expression at diagnosis in AML patients. There were not significant difference of OS between MPO+ and MPO- groups (p=0.208). (B) EFS by MPO expression at diagnosis in AML patients. Patients with MPO- group had an inferior DFS than in MPO+ group (1-year DFS; 26% vs. 50%, p=0.027). OS, overall survival; MPO, myloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; AML, acute myeloid leukemia; DFS, disease-free survival.

• 

  Fig. 2 (A) OS by MPO expression at diagnosis for AML patients received transplants. Among the patients received transplants. A similar difference of OS was observed (p=0.375). (B) DFS OS by MPO expression at diagnosis for AML patients received transplants. Among the patients received transplants. There were not significant difference between MPO+ and MPO- groups (p=0.289). (C) OS by MPO expression at diagnosis for AML patients not received transplants. There were not significant difference of OS between MPO+ and MPO- groups (p=0.398). (D) EFS by MPO expression at diagnosis for AML patients not received transplants were significant difference between two groups (p=0.012). OS, overall survival; MPO, myloperoxidase; MPO+, MPO-positive; MPO-, MPO-negative; AML, acute myeloid leukemia; DFS, disease-free survival.

Reference

1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. Joint Accreditation Committee, International Society for Cellular Therapy. European Group for Blood and Marrow Transplantation. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006. 37:1069–1085.

2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The Medical Research Council Adult and Childrens Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998. 92:2322–2333.

3. Grimwade D. Karp JE, editor. Impact of cytogenetics on clinical outcome in AML. Acute Myelogenous Leukemia. 2007. Totowa, New Jersey: Human Press;177–192.

4. Matsuo T, Kuriyama K, Miyazaki Y, Yoshida S, Tomonaga M, Emi N, et al. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia. 2003. 17:1538–1543.

5. Kuriyama K, Tomonaga M, Kobayashi T, Takeuchi J, Ohshima T, Furusawa S, et al. Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review. Int J Hematol. 2001. 73:93–99.

6. Matsuo T, Cox C, Bennett JM. Prognostic significance of myeloperoxidase positivity of blast cells in acute myeloblastic leukemia without maturation (FAB: M1): an ECOG study. Hematol Pathol. 1989. 3:153–158.

7. Takubo T, Kubota Y, Oguma S, Ueda T, Shibata H, Nakamura H, et al. [Classification of acute non-lymphocytic leukemia based on the distribution picture of peroxidase activity and cell size. Correlation between the classification and therapeutic response]. Nihon Ketsueki Gakkai Zasshi. 1983. 46:1209–1215.

8. Suĭć M, Boban D, Marković-Glamocak M, Petrovecki M, Marusić M, Labar B. Prognostic significance of cytochemical analysis of leukemic M2 blasts. Med Oncol Tumor Pharmacother. 1992. 9:41–45.

9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985. 103:620–625.

10. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995. 9:1783–1786.

11. Davidson JM, Gorringe KL, Chin SF, Orsetti B, Besret C, Courtay-Cahen C, et al. Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer. 2000. 83:1309–1317.

12. Sawayama Y, Miyazaki Y, Ando K, Horio K, Tsutsumi C, Imanishi D, et al. Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein. Leukemia. 2008. 22:956–964.

13. Beutler E, McMillan R, Spruce W. The role of bone marrow transplantation in the treatment of acute leukemia in remission. Blood. 1982. 59:1115–1117.

14. Gale RP, Kay HE, Rimm AA, Bortin MM. Bone-marrow transplantation for acute leukaemia in first remission. Lancet. 1982. 2:1006–1009.

15. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009. 385–395.